CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer

Individualizing the Selection of First-Line Therapy for Patients with HR-Positive Metastatic BCПодробнее

Addressing Current Questions and Controversies in the Management of Metastatic Breast CancerПодробнее

Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapi...Подробнее

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2...Подробнее

Dr Ma on Questions Regarding Treatment Sequencing in CDK4/6 Inhibitor–Resistant Breast CancerПодробнее

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Fu...Подробнее

Advances in the teatment of high-risk early-stage hormone receptor positive breast cancerПодробнее

Education Session: Treatment Post CDK 4/6 InhibitorsПодробнее

ER-Positive Metastatic Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives ...Подробнее

Updates on Breast Cancer Treatment: Exploring CDK4/6 Inhibitors & Endocrine TherapyПодробнее

2023 Updates In Metastatic Breast Cancer TreatmentПодробнее

The best sequence of endocrine treatment in metastatic luminal Breast Cancer:solving the puzzleПодробнее

Clinical and genomic landscape of breast cancers carrying CCNE1 amplificationПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Important considerations in the management of HR+, HER2-negative early breast cancerПодробнее

Genome-wide ctDNA assessment predicts outcome and resistance in HR+/HER2- MBC treated with CDK4/6iПодробнее

Endocrine therapy resistance in ER+ metastatic breast cancerПодробнее

CDK4/6 Inhibitors Combined with Endocrine Therapy in PALOMA-3 and MONALEESA-3 - Medpage TodayПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

What is the role of CDK4/6 inhibitors in early breast cancer?Подробнее